BMGL

Basel Medical Group Ltd is a holding company, which operates through its subsidiary, Basel Medical Group Pte. Ltd. It provides a wide spectrum of general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Its orthopedic treatments and surgery include non-surgical treatments, such as medications, injections, splinting and physiotherapy, and surgical orthopedic procedures, including minimally invasive treatments for complex surgeries. Its rehabilitative therapy provides in-house physiotherapy treatments, including post-surgery rehabilitation, as well as sports therapy. Its neurosurgical care covers treatments involving spinal and brain conditions, from headaches and brain tumors to spinal issues, aneurysms and strokes. It also specializes in diagnostic imaging and outpatient care.

Wall Street analysts forecast BMGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMGL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Basel Medical Group Ltd revenue for the last quarter amounts to 100.00 USD, decreased 0.00 % YoY.

Basel Medical Group Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

Basel Medical Group Ltd (BMGL) has 77 emplpoyees as of December 17 2025.

Today BMGL has the market capitalization of 14.31M USD.